# US 2001/0027198 A1 · Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027198 A1
- Document ID: US20010027198A1
- Status: Published application
- Kind: A1
- Application number: 09/818,339
- Filed: 2001-03-27
- Published: 2001-10-04
- Earliest claimed: 1997-10-27
- Assignees: Dr. Reddy's Research Foundation & Reddy- Cheminor, Inc.
- Inventors: Vidya Bhushan Lohray; Braj Brushan Lohray; Rao Bheema Paraselli; Rajagopalan Ramanujam; Ranjan Chakrabarti
- Web page: https://patentgrep.com/patent/US20010027198A1

## CPC

- C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C 235/48: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 327/48: having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07D 239/90: with acyclic radicals attached in position 2 or 3
- C07D 265/22: Oxygen atoms
- C07D 279/08: condensed with carbocyclic rings or ring systems
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β-aryl-α-oxysubstituted alkylcarboxylic acids of the general formula (1), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1 The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.

## Claims

### Claim 1

A compound of formula (I) 52
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutieally acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkIV, cycloalkll, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, hetero-aralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be mono or dialkyl amino group, arylamino, acylamino, aralkylamino, arninoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, hetero-aryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or di alkylamino group, arylamino, aralkyl-amino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, arylkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents or unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group or forms a bond with R8; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted ararryl, or R8 forms a bond together with R7; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloallyl, aryl, arallyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents oxygen or NR12, where R12 represents hydrogen, or unsubstituted or substituted alkyl, aryl, hydroxyalkyl, aralkyl, hetero-cyclyl, heteroaryl, or heteroaralkyl groups; R10 and R12 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, which may or unsubstituted or substituted contain one or more heteroatoms selected from oxygen, sulfur or nitrogen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom.

### Claim 2 (depends on 1)

A compound of the formula (I) according to claim 1, wherein the groups represented by R1-R4 and the groups R5 and R6 when attached to carbon atom are substituted, the substituents are selected from halogen, hydroxy, or nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroarallyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, aralkoxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

### Claim 3 (depends on 1, 2)

A compound of the formula (I) according to claims 1 or 2, wherein the groups R5 and R6 when attached to nitrogen are substituted, substituents are selected from halogen such as fluorine, chlorine; hydroxy, acyl, acyloxy, or amino groups.

### Claim 4 (depends on 1, 2, 3)

A compound of the formula (I) according to claim 1, 2 or 3, wherein the group Ar includes substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, benzoxazolyl, benzothiazolyl, indolyl, indolinyl, azaindolyl, azaindolinyl, indenyl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl, or pyrazolyl.

### Claim 5 (depends on 1, 2, 3, 4)

A compound of the formula (I) according to claim 1, 2, 3 or 4, wherein the substituents on the group represented by R9 are selected from halogen, hydroxy, formyl or nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cyclo-alkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkyl-amino, alkoxyalkyl, alkyitlio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

### Claim 6

A process for the preparation of compound of formula (I) 53
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, where X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxy-carbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acyl-amino, aralkylamino, arnnoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR1 I; R11 and the groups R5 and R6 when attached to nitrogen atom may be the same or different and represent hydrogen, hydroxy, formyl or,unsubstituted or substituted groups selected from alkyl, cyloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, hetero-cyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylarnino, alkylamino which may be mono or di alkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl; aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 together with R8 forms a bond; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents oxygen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, which comprises:
a) reacting a compound of formula (IIIa) 54
where all symbols are as defined above with a compound of formula (IIIb) 55
where R9 and R10 are as defined above excluding hydrogen and R13 represents (C1-C6)alkyl, to yield compound of formula (I) defined above;
b) reacting the compound of formula (IIIa) 56
where all symbols are as defined earlier with Wittig reagents;
c) reacting a compound of formula (IIIa) 57
where all other symbols are as defined above with a compound of formula (IIIc) 58
where R8 is hydrogen and all other symbols are as defined above to yield a compound of formula (I) as defined above after dehydration;
d) reacting a compound of formula (IIe) 59
where all symbols are as defined earlier and L1 represents a leaving group, with a compound of formula (IIId) 60
where R7 and R8 together represent a bond and all other symbols are as defined above to produce a compound of the formula (I) where all symbols are as defined above;
e) reacting a compound of formula (IIIf) 61
where all symbols are as defined above with a compound of formula (IIIg) 62
where R7 and R8 together represent a bond, L1 is a leaving group to produce a compound of formula (I) defined above where the linker group (CH2)n—O— is attached to nitrogen atom;
f) reacting a compound of formula (IIIh) 63
where all symbols are as defined above with a compound of formula (IIId) 64
where R7 and R8 together represent a bond and all other symbols are as defined above to produce a compound of formula (I) where all symbols are as defined above;
g) reacting a compound of formula (IIIi) 65
where all symbols are as defined above with a compound of formula (IIIj) 66
where R7 and R8 together represent a bond, R14 represents lower alkyl group and all other symbols are as defined above, to produce a compound of formula (I) defined above, where the linker group —(CH2)n—O— is attached to carbon atom;
h) reacting a compound of formula (Illk) 67
where all symbols are as defined above with a compound of formula (IIII) 68
where R9=R10 and are as defined above excluding hydrogen to produce a compound of the formula (I);
(i) reacting a compound of formula (IIIm) where R7, R8 together represent a bond and all other symbols are as defined above 69
with a compound of formula (IIIn) 70
where R14 represents lower alkyl group and all other symbols are as defined above, to produce a compound of formula (I) defined above, where the linker group —CH2)n—O— is attached to nitrogen atom; and
j) optionally converting the compounds of formula (I) obtained in any of the processes described above into pharmaceutically acceptable salts or pharmaceutically acceptable solvates.

### Claim 7

A process for the preparation of compound of formula (I) 71
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be amino or dialkyl group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyallyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralk6kxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyallyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl; R9 represents hydrogen or or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, arytoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents oxygen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, which comprises:
a) reducing a compound of formula (IVa) 72
which represents a compound of formula (I) where R7 and R8 together represent a bond and Y represents an oxygen atom and all other symbols are as defined above, to yield a compound of the formula (I) where R7 and R8 each represent hydrogen atom and all symbols are as definied above;
b) reacting a compound of formula (IVb) 73
where all symbols are as defined above and L2 is a leaving group with a compound of formula (IVc),
R9—OH (IVc)
where R9 represents unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylanmino-carbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups defined above;
c) reacting a compound of formula (IIIe) 74
where all symbols are as defined above and L1 is a leaving group with a compound of formula (IIId) 75
where all symbols are as defined above to produce a compound of the formula (I) defined above;
d) reacting a compound of formula (IIIh) 76
where all symbols are as defined above with a compound of formula (IIId) 77
where all symbols are as defined above to produce a compound of formula (I) defined above;
e) reacting a compound of formula (IVd) 78
which represents a compound of formula (I) where R9 represents a hydrogen atom and all other symbols are as defined above with a compound of formula (IVe)
R9—L2 (IVe)
where R9 represents or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups and L2 is a halogen atom to produce a compound of formula (I) defined above;
f) reacting a compound of the formula (IIIa) 79
where all symbols are as defined above with a compound of formula (IIIc) 80
where R8 is hydrogen, and all other symbols are as defined above to produce a compound of formula (I) after dehydroxylation;
g) reacting a compound of formula (IIIf) 81
where all symbols are as defined above with a compound of formula (IIIg) 82
where L1 is a leaving group, and all other symbols are as defined above to produce a compound of formula (I) defined above, where the linker group —CH2)n—O— is attached to nitrogen atom;
h) reacting a compound of formula (IIIi) 83
where all symbols are as defined above with a compound of general formula (IIIj) 84
where R14 represents a lower alkyl group, and all other symbols are as defined above, to produce a compound of formula (I) defined above, where the linker group —CH2)n—O— is attached to carbon atom;
i) converting a compound of formula (IVf) 85
where all symbols are as defined above to a compound of formula (I) defined above;
j) reacting a compound of formula (IVg) 86
where all symbols are as defined above with a compound of formula (IVc)
R9—OH (IVc)
where R9 is as defined above to produce a compound of formula (I), optionally;
(k) reacting a compound of formula (IIIm) where all symbols are as defined above 87
with a compound of formula (IIIn) 88
where R14 represents lower alkyl group and all other symbols are as defined above, to produce a compound of formula (I) defined above, where the linker group —(CH2)n—O— is attached to nitrogen atom;
l) resolving the compound of formula (I) obtained in any of the processes described above into its stereoisomers, and optionally;
m) converting the compounds of formula (I) or its stereoisomers obtained in any of the processes described above into pharmaceutically acceptable salts or pharmaceutically acceptable solvates.

### Claim 8

A process for the preparation of compound of formula (I) 89
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aryloxy, aralkyl-aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroarallyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxy-carbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxy-alkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxy-carbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylarmino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group or forms a bond with R8; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl, or R3 forms a bond together with R7; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloallyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkyl-aminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups;. R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents NR12, where R12 represents hydrogen or unsubstituted or substituted, alkyl, aryl, hydroxyalkyl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 and R12 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure contaning carbon atoms, which may or unsubstituted.or substituted contain one or more heteroatoms selected from oxygen, sulfur or nitrogen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, which comprises:
a) reacting a compound of formula (I) 90
where all symbols are as defined above and Y represents oxygen, and R10 represents hydrogen or a lower alkyl group or YR10 represents a halogen atom, or COYR10 represents a mixed anhydride group with appropriate amines of the formula NHR10OR12, where R10 and R12 are as defined earlier and, optionally;
b) resolving the compound of formula (I) obtained above into stereoisomers, and optionally;
c) converting the compounds of formula (I) obtained above into pharmnaceutically acceptable salts or pharmaceutically acceptable solvates.

### Claim 9 (depends on 6)

A compound of formula (I) 91
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, or its pharrnaceutically acceptable salts, its pharmaceutically acceptable solvates, where X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroarallcrl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxy-carbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acyl-amino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5, R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylithio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 together with R5 forms a bond; R9 represents hydrogen or or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents oxygen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, prepared according to the process of claim 6.

### Claim 10 (depends on 7)

A compound of formula (I) 92
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, araUlkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroarakyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acylamino, arakylamio, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalcyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be the same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylamino carbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents oxygen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, prepared according to the process of claim 7.

### Claim 11 (depends on 8)

A compound of formula (I) 93
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be mono or dialkylamino, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be the same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents art unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group or forms a bond with R8; R1 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl, or R8 forms a bond together with R7; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyallyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; Y represents NR12, where R12 represents hydrogen or unsubstituted or substituted groups selected from, alkyl, aryl, hydroxyalkyl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 and R12 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, which may or unsubstituted or substituted contain one or more heteroatoms selected from oxygen, sulfur or nitrogen; the linking group represented by —(CH2)n—O- may be attached either through nitrogen atom or carbon atom, prepared according to the process of claim 8.

### Claim 12

An intermediate of formula (IIIm) 94
where, X represents O or S; the groups R1, R2, R3 and R4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aryloxy, aralkyl,. aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amnino, alkylamino which may be mono or dialkylamino group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O or S; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group or forms a bond with R8; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl, or R8 forms a bond together with R7; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; and the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom.

### Claim 13 (depends on 12)

A process for the preparation of compound of formula (IIIm) as defined in claim 12, which comprises reacting a compound of formula (IVn) 95
where all symbols are as defined earlier with a compound of formula (IVo) 96
where all symbols are as defined earlier.

### Claim 14

An intermediate of formula (IVf) 97
where X represents O or S; the groups R1, R2, R3,4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroatalkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be morio or dialkylamino group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxy alkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonyl-amino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR1; R1and the groups R5 and R6 when attached to nitrogen atom may be the same or different and represent hydrogen, hydroxy, fornyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dic alkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group or forms a bond with R8; R8-represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl group or unsubstituted or substituted aralkyl or R8 forms a bond together with R7; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylamino-carbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; and the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom.

### Claim 15 (depends on 14)

A process for the preparation of compound of formula (IVf) defined in claim 14, where R7 and R8 represent hydrogen atoms and all other symbols are as defined in claim 14 which comprises:
a) reacting a compound of formula (IIIa) 98
where all symbols are as defined above with a compound of formula (IVi)
R9OCH2P+PPh3−Hal (IVi)
where R9 represents unsubstituted or substituted-groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups and Hal represents a halogen atom, to yield a compound of formula (IVj) 99
where all symbols are as defined above,
b) reacting the a compound of formula (IVj) with a compound of formula R9OH where R9 is as defined in part a to yield a compound of formula (IVk), 100
where are all symbols are as defined above, and
c) reacting a compound of formula (IVj) obtained above where all symbols are as defined above with trialkylsilyl cyanide to produce a compound of formula ([Vf) where all symbols are as defined above.

### Claim 16

An intermediate of formula (IVg) 101
where X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxy carbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloallcyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamnino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,.alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group; R10 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; and the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom.

### Claim 17 (depends on 14)

A process for the preparation of compound of formula (IVg) 102
where X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, alkylamino which may be mono or dialkylamino group, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino which may be mono or dialkylamino group, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, earboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1 - 4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents lo hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group; R10 represents hydrogen or unsubstituted or substituted groups selected from allyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; and the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, which comprises:
a) reacting a compound of formula (IIIe) 103
where L1 is a leaving group and all other symbols are as defined in claim 14 with a compound of formula (IVm) 104
where R8 is a hydrogen atom and all other symbols are as defined in claim 14, to yield a compound of formula (IVl) 105
where R1is a hydrogen atom and all other symbols are as defined above, and
b) reacting the compound of formula (IVl) obtained above with an appropriate diazotizing agent.

### Claim 18 (depends on 1)

A compound according to claim 1 which is selected from:
Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro- 1,3 -benzoxazin-3-yl]ethoxy]phenyl]-2-propenoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro- 1 ,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4dihydro-1 ,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(−)-Bthyl 2-ethoxy-3-[4-[2-[4-oxo-3,4dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[2-[4-oxo-3,4dihydro 1,3 benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts;
[2R, N(1S)] 2-Ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]-N—(2-hydroxy- 1 -phenylethyl)propanarnide;
[2S, N(1S)] 2-Ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1 ,3-benzoxazin-3-yl]ethoxy]phenyl]-N—(2-hydroxy-1-phenylethyl)propanamde;
(+)-2-Ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy] phenyl]propanoic acid and its salts;
(−)-2-Bthoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy] phenyl]propanoic acid and its salts;
(±)-Ethyl 2-phenoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]-2-propenoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[2,2-dimethyl-4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[2,2-dimethyl4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(−)-Ethyl 2-ethoxy-3-[4-[2-[2,2-dimethyl4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[2-[2,2dimethyl-4-xo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3-[4-[2-[2,2-dimethyl4-oko-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]pbenyl]propanoic acid and salts;
(−)-2-Ethoxy-3-[4-[2-[2,2-dimethyl-4-oxo-3,4-dihydro- 1,3-benzoxazin-3-yl]ethoxy]pbenyl]propanoic acid and its salts;
(+)-Methyl 2-ethoxy-3-[4-[[4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[[4-oxo-3 ,4-dihydro-1 ,3-benzoxazin-2-y1]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3-[4-[[4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoic acid and its salts;
(−)-2-Ethoxy-3-[4-[[4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoic acid and its salts;
(±)-Methyl 2ethoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxyjphenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]l phenyl]propanoate ;
(−)-2-ethoxy-3- [4-[[4 [oxo-1,2,3,4 -eetraydro-2-quinazolinyl]methoxy]phenyl]propanoic acid;
(+)-2-Ethoxy-3-[4-[[4-oxo- 1,2,3 ,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid;
(−)-2-Ethoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid;
(±)-Methyl 2ethoxy-3-[4-[[6-chloro4-oxo-1,2,3,4-tetrahydro-2-uinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2ethoxy-3-[4-[[6-chloro4-oxo-1,2,3,4-tetrahydro-2-uinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-2-Ethoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3-[4-[[6-chloro-4-oxo- 1 ,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(−)-2-Ethoxy-3-[4-[[6-chloro4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(+)-Methyl 2-ethoxy-3-[4-[[3-methyl4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[3-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[3-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(±)-Methyl 2-ethoxy-3-[4-[[3-methyl-4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[3-methyl-4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[3-methyl4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[[3 methyl4-oxo-3,4-dihydro- 1,3-benzoxazin-2-yl]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3-[4-[-methyl4-oxo-3 ,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoic acid and its salts;
(−)-2-Ethoxy-3-[4-[[3-methyl-4-oxo-3,4-dihydro-1,3-benzoxazin-2-yl]methoxy]phenyl]propanoic acid and its salts;
(+)-Methyl 2-ethoxy-3-[4-[[3-ethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[3-ethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[3-ethyl4-oxo-1,2,3,4-tetIahydro-2-uinazolinyl]methoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[[3-ethyl-4-oxo-1 ,2,3,-4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3 -[4-[[3 -ethyl-4-oxo- 1,2,3 ,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(−)-2-Ethoxy-3-[4-[[3-ethyl-4-oxo- 1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(±)-Methyl 2-ethoxy-3-[4-[[1,3-dirnethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2-ethoxy-3-[4-[[1,3Aimethyl-4-oxo-1 ,2,3,4-tetrahydro-2-uinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-ethoxy-3-[4-[[1,3dimethyl-4-oxo-1 ,2,3,4-tetrahydro-2iuinazolinyl]methoxy]phenyl]propanoate;
(±)-2-Etlioxy-3-[4-[[1,3-dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phcnyl]propanoic acid and salts;
(+)-2-Ethoxy-3-[4-[[1,3-dimnethyl-4-xo- 1,2,3 ,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and salts;
(−)-2-Ethoxy-3-[4-[[1,3-dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and salts;
(±)-Methyl 2-phenoxy-3-[4-[[4-oxo-1 ,2,3 ,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2-phenoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(−)-Methyl 2-phenoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-2-Phenoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazoliny l]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Phenoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-uinazolinyl]methoxy]phenYl]propanoic acid and its salts;
(−)-2-Phenoxy-3-[4-[[4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(±)-Methyl 2-phenoxy-3-[4-[[6-chloro-4oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(+)-Methyl 2-phenoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]henyl]propanoate;
(−)-Methyl 2-phenoxy-3-[4-[[6-chloro-4-oxo-1,2,3 ,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoate;
(±)-2-Phenoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(+)-2-Phenoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(−)-2-Phenoxy-3-[4-[[6-chloro-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl]propanoic acid and its salts;
(±)-Ethyl 2-ethoxy-3 -[4-[2-[6-nitro-4-oxo-3,4-dihydro- 1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[6-nitro-4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(−)-Ethyl 2-ethoxy-3-[4-[2-[6-nitro-4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(±)-2-Ethoxy-3-[4-[2-[6-nitro4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and it s salts;
(+)-2-Ethoxy-3-[4-[2-[6-nitro4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts;
(−)-2-Ethoxy-3-[4-[2-[6-nitro4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts;
(±)-Ethyl 2-ethoxy-3 - [4-[2-[6- acet yl4oxo -3 ,4-dihydro-y1,3 -benzoxazin-3 -yl]e thoxy]phenyl]propanoate;
(+)-Ethyl 2-ethoxy-3-[4-[2-[6-acetyl4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(−)-Ethyl 2-ethoxy-3-[4-[2-[6-acetyl4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;
(+)-2-Ethoxy-3-[4-[2-[6-acetyl-4-oxo-3,4-dihydro- 1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts;
(+)-2-Ethoxy-3 -[4-[2-[6-acetyl-4-oxo-3 ,4-dihydro- 1,3-benzoxazin-3 -yl]ethoxy]phenyl]propanoic acid and its salts; and
(−)-2-Ethoxy-3-[4-[2-[6-acetyl4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoic acid and its salts.

### Claim 19 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

A pharmaceutical composition which comprises a compound of formula (I) 106
as defined in any one of claims 1-5, 9-11 or 18 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

### Claim 20 (depends on 19)

A pharmaceutical composition as claimed in claim 19, in the form of a tablet, capsule, powder, syrup, solution or suspension.

### Claim 21 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18, 19)

A method of preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering an effective amount compound of formula (I) as defined in any one of claims 1-5, 9-11 or 18 or a pharmaceutical composition as claimed in claims 19 and to a patient in need thereof.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 23 (depends on 22)

A method according to claim 22, for the treatment prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPARα, PPARγ or a mixture thereof of formula (I).

### Claim 24 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18, 19, 20)

A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma comprising administering a compound of formula (I) as defined in any one of claims 1-5, 9-11 or 18 or a pharmaceutical composition as claimed in claims 19 and 20 to a patient in need thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 19, 20)

A method of preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in any one of claims 1-5, 9-11, or 18 or a pharmaceutical composition as claimed in claims 19 and 20 in combination/ concornittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergestically together to a patient in need thereof.

### Claim 26 (depends on 25)

A method according to claim 25, wherein the disease is type II diabetes, impaired. glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 27 (depends on 26)

A method according to claim 26 for the treatment or prevention of disorders related to Syndrome X, which comprises administering a compound of formula (I) in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergestically together.

### Claim 28 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18, 19, 20)

A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma, which comprises administering a compound of formula (I) claimed in in any one of claims 1-5, 9-11 or 18 or a pharmaceutical composition as claimed in claims 19 and 20 in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergestically together.

### Claim 29 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

Use of a compound according to any one of claim 1-5, 9-11 or 18 for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis,. obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.

### Claim 30 (depends on 29)

Use according to claim 29, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 31 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

Use of a compound according to any one of claims 1-5, 9-11 or 18 for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma.

### Claim 32 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

Use of a compound according to any one of claim 1-5, 9-11 or 18 for preparing a medicament for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.

### Claim 33 (depends on 32)

Use according to claim 32, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 34 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

Use of a compound according to any one of claims 1-5, 9-11 or 18 for preparing a medicament for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma.

### Claim 35 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

A medicine for preventing or treating hypertipemia, hypercholesteremia, hyper glycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering an effective amount compound of formula (I) as defined in any one of claims 1-5, 9-11 or 18 to a patient in need thereof.

### Claim 36 (depends on 35)

A medicine according to claim 35, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, to obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 37 (depends on 27)

A method according to claim 27, for the treatment or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPARα, agonist of PPARγ or a mixture thereof of formula (I).

### Claim 38 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 18)

A medicine for reducing plasma glucose, triglycerides, totalcholesterol, LDL, VLDL and free fatty acids in the plasma comprising administering a compound of formula (I) as defined in any one of claims 1-5, 9-11 or 18 to a patient in need thereof.

### Claim 39 (depends on 1, 2, 3, 4, 5, 9, 10, 11)

A medicine for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in any one of claims 1-5, 9-11, or 18 in combinationkconcomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergestically together to a patient in need thereof.

### Claim 40 (depends on 39)

A medicine according to claim 39, wherein the disease is type 1I diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephroscierosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive fimctions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 41 (depends on 6, 7)

A process for the preparation of compound of formula (I) 107
its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharrnaceutically acceptable solvates, wherein X represents O or S; the groups R1, R2, R3, R4 and the groups R5 and R6 when attached to carbon atom may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl; or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, monoalkylamino, dialkylamino, arylamino, acylamino, aralkylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; W represents O, S or a group NR11; R11 and the groups R5 and R6 when attached to nitrogen atom may be the same or different and represent hydrogen, hydroxy, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, carboxylic acid derivatives, or sulfonic acid derivatives; n is an integer ranging from 1-4; Ar represents an unsubstituted or substituted divalent aromatic or heterocyclic group; R7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, or unsubstituted or substituted aralkyl group; R8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, acyl or unsubstiuted or substituted aralkyl; R9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; R10 represents hydrogen; Y represents oxygen; the linking group represented by —(CH2)n—O— may be attached either through nitrogen atom or carbon atom, which comprises: hydrolising a compound of formula (I) described in any of the claims 6 and 7 where R10 represents unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups and all other symbols are as defined earlier by conventional methods.

### Claim 42 (depends on 1, 2, 3, 4, 5, 19, 20)

Use of a compound of formula (I) as defined in any one of claims 1-5; 9-11, or 18 or a pharmaceutical composition as claimed in claim 19 or 20 in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.

### Claim 43 (depends on 42)

Use according to claim 42, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia; disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 44 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 19, 20)

Use of a compound as defined in any one of claims 1-5, 9-11, or 18 or a pharmaceutical composition as claimed in claim 19 or 20 in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma.

### Claim 45 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 19, 20)

Use of a compound of formula (I) as defined in any one of claims 1-5, 9-11, or 18 or a pharmaceutical composition as claimed in claim 19 or 20 for preparing a medicament in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.

### Claim 46 (depends on 45)

Use according to claim 45, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

### Claim 47 (depends on 1, 2, 3, 4, 5, 9, 10, 11, 19, 20)

Use of a compound as defined in any one of claims 1-5, 9-11, or 18 or a pharmaceutical composition as claimed in claim 19 or 20 for preparing a medicament in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma.
